SWOG clinical trial number
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

Trial of Cystectomy Alone Versus Neoadjuvant M-VAC +Cystectomy in Patients with Locally Advanced Bladder Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Local Bladder
Activated
08/01/1987
Closed
07/01/1998

Research committees

Genitourinary Cancer

Treatment

MVAC

Publication Information Expand/Collapse

2021

Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times

Z McCaw;A Odisho;H Chaparala;M Yin;J Cloyd;R Svatek;WE Carson;CT Lee;D Sundi Urologic Oncology (Seminars and Original Investigations) Jul;39(7):435.e17-435.e22

PMid: PMID33436327

2020

Economic evaluations in NCI-sponsored network cancer clinical trials

VT Nghiem;R Vaidya;GH Lyman;DL Hershman;SD Ramsey;JM Unger Value in Health Dec;23(12):1653-1661. doi: 10.1016/j.jval.2020.08.2095. Epub 2020 Oct 9

PMid: PMID33248521 | PMC number: PMC8262264

Association of Patient Demographic Characteristics and Insurance Status with Survival in Cancer Randomized Clinical Trials with Positive Findings

JM Unger;CD Blanke;M Leblanc;W Barlow;R Vaidya;M Fleury;SD Ramsey;DL Hershman JAMA Network Open Apr 1;3(4):e203842

PMid: PMID32352530 | PMC number: PMC7193331

2018

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2017

The effect of positive SWOG treatment trials on survival of patients with cancer in the US population

JM Unger;M Leblanc;CD Blanke JAMA Oncology Oct 1;3(10):1345-1351

PMid: PMID28586789; PMC5710507

The impact of positive SWOG treatment trials on population survival

J Unger;M LeBlanc;C Blanke J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion

2016

Validating a local failure risk stratification for use in prospective studies of adjuvant radiation therapy for bladder cancer

B Baumann;J He;W Hwang;KN Tucker;JE Bekelman;H Herr;SP Lerner;TJ Guzzo;SB Malkowicz;J Christodouleas International Journal of Radiation Oncology, Biology, and Physics, Jun 1;95(2):703-706

PMid: PMID27020106 | PMC number: PMC5126649

Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

E Ojerholm;A Smith;W-T Hwang;B Baumann;KN Tucker;SP Lerner;R Mamtani;B Boursi;JP Christodouleas Cancer 2017 Mar 1;123(5):794-801; Oct 27. doi: 10.1002/cncr.30422. [Epub ahead of print]

PMid: PMID27787873 | PMC number: PMC5319875

2014

Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort

B Baumann;J He;W-T Hwang;K Tucker;S Lerner;C Tangen;H Herr;T Guzzo;SB Malkowicz;JP Christodoulea Journal of Clinical Oncology 32(suppl 4; abstr297); ASCO Genitourinary Cancer Symposium, poster presentation;

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

2013

Risk stratification for local-regional failure after cystectomy

BC Bauman;J He;H Hwang;K Tucker;SP Lerner;CM Tangen;HW Herr;T Guzzo;SB Malkowicz;J Christodouleas American Urological Association 2013 Annual Meeting, Abstract #1628; moderated poster discussion;

Robust risk stratification model predicts local-regional recurrence after radical cystectomy in different patient cohorts

B Baumann;J He;W-T Hwang;K Tucker;S Lerner;C Tangen;H Herr;T Guzzo;SB Malkowicz;J Christodouleas International Journal of Radiation Oncology * Biology * Physics 87(2):Supplement, p. S82; ASTRO annual meeting Sept. 22-25, 2013, Atlanta, GA), oral presentation;

2011

Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer treated with radical cystectomy? A secondary analysis of Southwest Oncology Group-directed intergroup study (S8710) [PMID 21105991; PMC3117124

E Scosyrev;B Ely;EM Messing;VO Speights;HB Grossman;DP Wood;RW de Vere White;NJ Vogelzang;DL Trump;RB Natale;CM Tangen;ED Crawford;IM Thompson British Journal of Urology Internatonal, 108(5):693-699;

2010

Do mixed histologic features affect survival benefit from neo-adjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?

E Scosyrev;B Ely;EM Messing;VO Speights;HB Grossman;DP Wood;R de Vere White;N Vogelzang;D Trump;R Natale;C Tangen;ED Crawford;IM Thompson Journal of Urology 183(4):suppl. E659 (abstr #1708); AUA 2010 Annual Meeting;poster

Do mixed histologic features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer?

EM Messing;E Scosyrev;HB Grossman;R de Vere White;DL Trump;RB Natale;C Tangen;ED Crawford;IM Thompson ASCO 2010 Genitourinary Cancers Symposium, abstr. #274; oral

2009

Quality of pathologic response and surgery correlate with survival for completely resected bladder cancer following neoadjuvant MVAC

G Sonpavde;B Goldman;VO Speights;SP Lerner;DP Wood;NJ Vogelzang;DL Trump;RB Natale;HB Grossman;ED Crawford ASCO 2009 GU Cancers Symposium, abst. #249

Quality of pathologic response and surgery correlate with survival for completely resected bladder cancer following neoadjuvant chemotherapy. 2009 [PMID19517476; PMC3079554]

G Sonpavde;B Goldman;VO Speights;SP Lerner;DP Wood;SP Lerner;DL Trump;RB Natale;HB Grossman;ED Crawford Cancer 115(18):4104-4109

2008

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2005

Optimal combined modality treatment improves outcome of locally advanced bladder cancer: analyis of SWOG 8710

ZA Dotan;DF Bajorin;BH Grossman;HW Herr Proc of the ASCO, JCO 23(16S):385s (#4531)

2004

Surgical factors influence bladder cancer outcomes: a Cooperative Group report

HW Herr;JR Faulkner;HB Grossman;RB Natale;R de Vere White;MF Sarosdy;ED Crawford Journal of Clinical Oncology 22(14):2781-2789

Pathologic evaluation of radical cystectomy specimens: a Cooperative Group report

HW Herr;JR Faulkner;HB Grossman;ED Crawford Cancer 100(11):2470-2475

2003

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

HB Grossman;RB Natale;CM Tangen;VO Speights;NJ Vogelzang;DL Trump;RW de Vere White;MF Sarosdy;DP Wood Jr;D Raghavan;ED Crawford New England Journal of Medicine 349(9):859-866

Surgical variables impact bladder cancer outcomes: a cooperative group report.

HW Herr;J Faulkner;HB Grossman;ED Crawford Proc of the American Society of Clinical Oncology 22:383(#1540)

Southwest Oncology Group studies in bladder cancer

ED Crawford;DP Wood;DP Petrylak;J Scott;CA Coltman, Jr;D Raghavan Cancer Supplement 97(8):2099-2108

2001

SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer.

D Crawford;B Grossman;B Blumenstein;N Vogelzang;D Trump;VO Speights;R DeVere White;R Natale Journal of Urology 165(5)Suppl:260(#1069)

SWOG 8710 (INT-0080): randomized phase III trial of neoadjuvant MVAC + cystectomy versus cystectomy alone in patients with locally advanced bladder cancer

RB Natale;HB Grossman;B Blumenstein;N Vogelzang;DL Trump;VO Speights;R deVere White;ED Crawford Proc of the American Society of Clinical Oncology 20:2a(#3)

Other Clinical Trials

SWOG Clinical Trial Number
S2312
SWOG Clinical Trial Number
S2210

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200